[go: up one dir, main page]

TWI350291B - Crystal of anti-egfr antibodies - Google Patents

Crystal of anti-egfr antibodies

Info

Publication number
TWI350291B
TWI350291B TW093136625A TW93136625A TWI350291B TW I350291 B TWI350291 B TW I350291B TW 093136625 A TW093136625 A TW 093136625A TW 93136625 A TW93136625 A TW 93136625A TW I350291 B TWI350291 B TW I350291B
Authority
TW
Taiwan
Prior art keywords
crystal
egfr antibodies
egfr
antibodies
Prior art date
Application number
TW093136625A
Other languages
English (en)
Other versions
TW200530268A (en
Inventor
Susanne Matheus
Hanns-Christian Mahler
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34625406&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TWI350291(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of TW200530268A publication Critical patent/TW200530268A/zh
Application granted granted Critical
Publication of TWI350291B publication Critical patent/TWI350291B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C30—CRYSTAL GROWTH
    • C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
    • C30B7/00—Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Metallurgy (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Materials Engineering (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
TW093136625A 2003-11-29 2004-11-26 Crystal of anti-egfr antibodies TWI350291B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10355904A DE10355904A1 (de) 2003-11-29 2003-11-29 Feste Formen von anti-EGFR-Antikörpern

Publications (2)

Publication Number Publication Date
TW200530268A TW200530268A (en) 2005-09-16
TWI350291B true TWI350291B (en) 2011-10-11

Family

ID=34625406

Family Applications (1)

Application Number Title Priority Date Filing Date
TW093136625A TWI350291B (en) 2003-11-29 2004-11-26 Crystal of anti-egfr antibodies

Country Status (21)

Country Link
US (1) US7960516B2 (zh)
EP (2) EP1686961A1 (zh)
KR (2) KR20060111539A (zh)
CN (1) CN1886118A (zh)
AR (1) AR046677A1 (zh)
AU (1) AU2004292742B9 (zh)
BR (1) BRPI0416968A (zh)
CA (1) CA2547446C (zh)
CO (1) CO5690537A2 (zh)
DE (1) DE10355904A1 (zh)
EC (1) ECSP066681A (zh)
IL (1) IL175935A (zh)
MX (1) MXPA06005968A (zh)
MY (1) MY148228A (zh)
NZ (1) NZ548210A (zh)
PE (1) PE20050667A1 (zh)
RU (1) RU2397755C2 (zh)
TW (1) TWI350291B (zh)
UA (1) UA84893C2 (zh)
WO (1) WO2005051355A1 (zh)
ZA (1) ZA200605348B (zh)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7060808B1 (en) * 1995-06-07 2006-06-13 Imclone Systems Incorporated Humanized anti-EGF receptor monoclonal antibody
US20030224001A1 (en) * 1998-03-19 2003-12-04 Goldstein Neil I. Antibody and antibody fragments for inhibiting the growth of tumors
ZA200007412B (en) * 1998-05-15 2002-03-12 Imclone Systems Inc Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases.
RU2294761C2 (ru) * 1999-05-14 2007-03-10 Имклон Систимс Инкопэритид Лечение резистентных опухолей человека антагонистами рецепторов фактора роста эпидермиса
WO2002011677A2 (en) * 2000-08-09 2002-02-14 Imclone Systems Incorporated Treatment of hyperproliferative diseases with epidermal growth factor receptor antagonists
US20080008704A1 (en) * 2001-03-16 2008-01-10 Mark Rubin Methods of treating colorectal cancer with anti-epidermal growth factor antibodies
US20080026068A1 (en) * 2001-08-16 2008-01-31 Baxter Healthcare S.A. Pulmonary delivery of spherical insulin microparticles
WO2003057179A2 (en) 2002-01-11 2003-07-17 Biomarin Pharmaceutical, Inc. Use of p97 as an enzyme delivery system for the delivery of therapeutic lysosomal enzymes
EP1622941A2 (en) * 2003-03-20 2006-02-08 ImClone Systems Incorporated Method of producing an antibody to epidermal growth factor receptor
CA2560305C (en) * 2004-03-19 2016-07-05 Imclone Systems Incorporated Human anti-epidermal growth factor receptor antibody
WO2005112894A1 (en) 2004-05-12 2005-12-01 Baxter International Inc. Nucleic acid microspheres, production and delivery thereof
WO2005112893A1 (en) * 2004-05-12 2005-12-01 Baxter International Inc. Microspheres comprising protein and showing injectability at high concentrations of said agent
US8728525B2 (en) * 2004-05-12 2014-05-20 Baxter International Inc. Protein microspheres retaining pharmacokinetic and pharmacodynamic properties
WO2005112885A2 (en) 2004-05-12 2005-12-01 Baxter International Inc. Oligonucleotide-containing microspheres, their use for the manufacture of a medicament for treating diabetes type 1
CA2942128C (en) 2006-08-04 2019-11-26 Baxter Healthcare S.A. Microsphere-based composition for preventing and/or reversing new-onset autoimmune diabetes
MX2009004351A (es) 2006-10-27 2009-05-12 Abbott Biotech Ltd Anticuerpos anti-htnfalfa cristalinos.
JP5744513B2 (ja) 2007-04-17 2015-07-08 バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ 肺送達のための核酸微小粒子
WO2009020654A1 (en) * 2007-08-08 2009-02-12 Abbott Laboratories Compositions and methods for crystallizing antibodies
JP2011500054A (ja) * 2007-10-15 2011-01-06 バイオジェン・アイデック・エムエイ・インコーポレイテッド 安定な保存用中間体を使用した生物製剤の製造方法
US8367427B2 (en) 2008-08-20 2013-02-05 Baxter International Inc. Methods of processing compositions containing microparticles
US8323685B2 (en) 2008-08-20 2012-12-04 Baxter International Inc. Methods of processing compositions containing microparticles
US8323615B2 (en) 2008-08-20 2012-12-04 Baxter International Inc. Methods of processing multi-phasic dispersions
US10143652B2 (en) * 2009-09-23 2018-12-04 Curirx Inc. Methods for the preparation of liposomes
CN102153648B (zh) * 2011-01-27 2012-07-04 中国人民解放军军事医学科学院生物工程研究所 一种抗egfr人源化抗体l4-h3及其编码基因与应用
ES2582869T3 (es) 2011-07-05 2016-09-15 Bioasis Technologies Inc Conjugados de P97-anticuerpo
US8722019B2 (en) 2011-08-05 2014-05-13 Bioasis Technologies, Inc. P97 fragments with transfer activity
CN104662150B (zh) 2012-07-31 2018-07-10 比奥阿赛斯技术有限公司 脱磷酸化的溶酶体贮积症蛋白及其使用方法
ES2774549T3 (es) 2013-03-13 2020-07-21 Bioasis Technologies Inc Fragmentos de P97 y usos de los mismos
WO2015031673A2 (en) 2013-08-28 2015-03-05 Bioasis Technologies Inc. Cns-targeted conjugates having modified fc regions and methods of use thereof
EP3102608B1 (en) 2014-02-03 2019-09-18 Bioasis Technologies Inc. P97 fusion proteins
AU2015219339B2 (en) 2014-02-19 2020-03-05 Bioasis Technologies Inc. P97-IDS fusion proteins
AU2015252906C1 (en) 2014-05-01 2020-09-17 Bioasis Technologies Inc. p97-polynucleotide conjugates
CN107001617B (zh) * 2014-12-04 2019-08-27 德鲁塔负富莱制药股份有限公司 Peg衍生物
CN106794258B (zh) * 2015-02-15 2019-07-12 江苏恒瑞医药股份有限公司 配体-细胞毒性药物偶联物、其制备方法及其应用
WO2016131409A1 (zh) * 2015-02-17 2016-08-25 上海美雅珂生物技术有限责任公司 抗体药物偶联物
AR103726A1 (es) 2015-02-27 2017-05-31 Merck Sharp & Dohme Cristales de anticuerpos monoclonales anti-pd-1 humanos
TW201709932A (zh) * 2015-06-12 2017-03-16 西雅圖遺傳學公司 Ｃｄ１２３抗體及其共軛物
ES2955961T3 (es) * 2015-06-30 2023-12-11 Seagen Inc Anticuerpos anti-ntb-a y composiciones y métodos relacionados
CN105810072A (zh) * 2016-03-25 2016-07-27 淮海工学院 一种蛋白质结晶的教学试剂盒及其方法
CN116333130A (zh) 2016-05-24 2023-06-27 英斯梅德股份有限公司 抗体及其制备方法
SG11201909955XA (en) 2017-05-02 2019-11-28 Merck Sharp & Dohme Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
WO2018218633A1 (en) 2017-06-02 2018-12-06 Beijing Percans Oncology Co. Ltd. Combination therapies for treating cancers
WO2019195959A1 (en) 2018-04-08 2019-10-17 Cothera Biosciences, Inc. Combination therapy for cancers with braf mutation
WO2019243159A1 (de) * 2018-06-18 2019-12-26 Bayer Aktiengesellschaft Gegen cxcr5 gerichtete binder-wirkstoff-konjugate mit enzymatisch spaltbaren linkern und verbessertem wirkungsprofil
BR112021002622A2 (pt) 2018-08-13 2021-05-11 Beijing Percans Oncology Co. Ltd. biomarcadores para terapia de câncer
US20230009076A1 (en) * 2019-06-28 2023-01-12 Serina Therapeutics, Inc. Polyoxazoline-drug conjugates with novel pharmacokinetic properties
CA3128035A1 (en) 2020-08-13 2022-02-13 Bioasis Technologies, Inc. Combination therapies for delivery across the blood brain barrier
CA3200812A1 (en) * 2020-12-04 2022-06-09 Qingsong GUO Antibody-drug conjugate, and intermediate thereof, preparation method thereof, and application thereof
CN115073437B (zh) * 2021-03-11 2023-07-18 北京师范大学 基于二氰基吡喃的大环多胺[12]aneN3化合物及其制备方法与用途
CN114652826B (zh) * 2022-01-24 2022-10-14 景泽生物医药(合肥)有限公司 抗egfr抗体的用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
AU4128089A (en) 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5747469A (en) 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
CA2082160C (en) * 1991-03-06 2003-05-06 Mary M. Bendig Humanised and chimeric monoclonal antibodies
WO1993000807A1 (en) 1991-07-03 1993-01-21 Cryolife, Inc. Method for stabilization of biomaterials
WO1994002602A1 (en) 1992-07-24 1994-02-03 Cell Genesys, Inc. Generation of xenogeneic antibodies
DK0586002T3 (da) 1992-08-18 2000-06-19 Centro Inmunologia Molecular Monoklonale antistoffer, som genkender epidermisvækstfaktor-receptoren, celler og fremgangsmåder heraf og præparater indeho
ES2304786T3 (es) 1995-04-27 2008-10-16 Amgen Fremont Inc. Anticuerpos anti-il-8 humanos, derivados a partir de xenoratones inmunizados.
US7060808B1 (en) 1995-06-07 2006-06-13 Imclone Systems Incorporated Humanized anti-EGF receptor monoclonal antibody
JPH11507535A (ja) * 1995-06-07 1999-07-06 イムクローン システムズ インコーポレイテッド 腫瘍の成長を抑制する抗体および抗体フラグメント類
EP0852951A1 (de) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
GB9904387D0 (en) 1999-02-25 1999-04-21 Pharmacia & Upjohn Spa Antitumour synergistic composition
CA2433353C (en) * 2000-12-28 2017-03-21 Altus Biologics, Inc. Crystals of whole antibodies and fragments thereof and methods for making and using them
US20020197261A1 (en) * 2001-04-26 2002-12-26 Chun Li Therapeutic agent/ligand conjugate compositions, their methods of synthesis and use
DE10133394A1 (de) 2001-07-13 2003-01-30 Merck Patent Gmbh Flüssige Formulierung enthaltend Cetuximab
DE10163459A1 (de) * 2001-12-21 2003-07-03 Merck Patent Gmbh Lyophilisierte Zubereitung enthaltend Antikörper gegen EGF-Rezeptor
US20110142822A1 (en) * 2004-06-14 2011-06-16 Kussie Paul H Crystal of egfr extracellular domain and cetuximab fab fragment, and uses thereof

Also Published As

Publication number Publication date
KR20120093406A (ko) 2012-08-22
PE20050667A1 (es) 2005-09-27
WO2005051355A1 (de) 2005-06-09
CO5690537A2 (es) 2006-10-31
CA2547446C (en) 2013-05-14
RU2397755C2 (ru) 2010-08-27
AU2004292742B9 (en) 2011-11-24
ZA200605348B (en) 2007-04-25
EP1974723A2 (de) 2008-10-01
ECSP066681A (es) 2006-10-25
KR20060111539A (ko) 2006-10-27
AU2004292742A1 (en) 2005-06-09
EP1974723A3 (de) 2010-06-09
MY148228A (en) 2013-03-29
AR046677A1 (es) 2005-12-14
NZ548210A (en) 2010-10-29
CA2547446A1 (en) 2005-06-09
TW200530268A (en) 2005-09-16
UA84893C2 (en) 2008-12-10
US20070122411A1 (en) 2007-05-31
IL175935A (en) 2013-10-31
DE10355904A1 (de) 2005-06-30
AU2004292742B2 (en) 2011-08-25
BRPI0416968A (pt) 2007-02-21
MXPA06005968A (es) 2006-07-06
CN1886118A (zh) 2006-12-27
US7960516B2 (en) 2011-06-14
RU2006123005A (ru) 2008-01-20
IL175935A0 (en) 2006-10-05
EP1686961A1 (de) 2006-08-09

Similar Documents

Publication Publication Date Title
TWI350291B (en) Crystal of anti-egfr antibodies
SI1587542T1 (sl) Uporaba anti-cd100 protiteles
IL243914A0 (en) Antibodies against vegf
IL246594A0 (en) Treatment with anti-vegf antibodies
IL173273A0 (en) Modified human igf-1r antibodies
IL172843A0 (en) Multivalent carriers of bi-specific antibodies
PL378412A1 (pl) Cząsteczki przeciwciał o specyficzności względem ludzkiej IL-1ß
GB0325192D0 (en) Method of use
IL212419A0 (en) Methods of administering anti-tnf antibodies
HK1087131A1 (en) Anti-igfr1 antibody therapeutic combinations
SI2374819T1 (sl) Protitelesa proteina MASP-2
AU2003265522A1 (en) FCGammaRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
GB0426043D0 (en) Antibodies
HK1155670A1 (en) Therapeutic use of anti-cs1 antibodies
IL174770A0 (en) Anti-insulin-like growth factor-i-receptor antibodies
AU2003277832A8 (en) Humanized tissue factor antibodies
IL172511A0 (en) Specific human antibodies
IL172533A0 (en) Humanized anti-ccr2 antibodies and methods of use
GB0301450D0 (en) Protein crystal structure
PL377902A1 (pl) Nowe zastosowanie kompleksu fosfor-azot-metal
HK1216427A1 (zh) 針對 的人抗體分子
PL1622926T3 (pl) Nowy sposób i produkty pośrednie wytwarzania związków 19-norsteroidów fluorowcowanych w pozycji 17
GB0108287D0 (en) Methods of crystal optimisation
GB0325391D0 (en) Human monoclonal antibodies
SI1656391T1 (sl) Modificirana humana IGF-1R protitelesa

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees